Jubilant Pharmova Q2 Results: Net profit falls as sterile injectables, radiopharma earnings decline

Jubilant Pharmova reported its Q2 FY27 results, showing a sharp drop in net profit despite a rise in revenue. The company's consolidated net profit fell by 74.1% year-on-year to ₹31.2 crore, while revenue from operations grew 20.5% to ₹2,370 crore. This divergence indicates that while the business is expanding, it is becoming less efficient at turning sales into earnings.

The decline in profit was driven by lower earnings from its sterile injectables and radiopharma segments. Consequently, the company's EBITDA dropped 29.3% to ₹241 crore, and its operating margin narrowed significantly from 17.4% to 10.2%. This margin compression is a key metric for investors to monitor as it signals rising costs or pricing pressures in the company's core operations.

Investors should watch for management commentary on the reasons behind the margin contraction and the outlook for the remaining quarters. It is also important to track the performance of the radiopharma segment, which has been a key growth driver for the company. The stock's reaction to these results will likely depend on whether investors view the margin decline as a temporary issue or a sign of structural challenges.